Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients

Abstract The prognosis of the coronavirus disease 2019 (COVID-19) patients is variable and depends on several factors. Current data about the impact of chronic obstructive pulmonary disease (COPD) and smoking on the clinical course of COVID-19 are still controversial. This study evaluated the preval...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Donato Lacedonia, Giulia Scioscia, Carla Santomasi, Paolo Fuso, Giovanna Elisiana Carpagnano, Andrea Portacci, Franco Mastroianni, Giovanni Larizza, Eugenio Sabato, Emanuela Profilo, Emanuela Resta, Maria Pia Foschino Barbaro, Onofrio Resta
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/214bc99f4fef4e3e8e845549b9efef60
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:214bc99f4fef4e3e8e845549b9efef60
record_format	dspace
spelling	oai:doaj.org-article:214bc99f4fef4e3e8e845549b9efef602021-12-02T17:18:21ZImpact of smoking, COPD and comorbidities on the mortality of COVID-19 patients10.1038/s41598-021-98749-42045-2322https://doaj.org/article/214bc99f4fef4e3e8e845549b9efef602021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98749-4https://doaj.org/toc/2045-2322Abstract The prognosis of the coronavirus disease 2019 (COVID-19) patients is variable and depends on several factors. Current data about the impact of chronic obstructive pulmonary disease (COPD) and smoking on the clinical course of COVID-19 are still controversial. This study evaluated the prevalence and the prognosis of COPD patients and smokers in a cohort of 521 patients admitted to four intermediate Respiratory Intensive Care Units (Puglia, Italy) with respiratory failure due to COVID-19 pneumonia. The prevalence of COPD and current smokers was 14% and 13%, respectively. COPD patients had a higher 30-day all-cause mortality than non-COPD patients. Former smokers compared to never smokers and current smokers had higher 30-day all-cause mortality. COPD patients and former smokers had more comorbidities. This study described the prevalence and the outcomes of COPD patients and smokers in a homogenous cohort of COVID-19 patients. The study showed that the prevalence of COPD and current smokers was not high, suggesting that they were not at increased risk of getting the infection. However, when SARS-CoV-2 infection occurred, COPD patients and former smokers were those with the highest all-cause mortality, which seemed to be mainly related to the presence of comorbidities and not to COPD and smoking itself.Donato LacedoniaGiulia SciosciaCarla SantomasiPaolo FusoGiovanna Elisiana CarpagnanoAndrea PortacciFranco MastroianniGiovanni LarizzaEugenio SabatoEmanuela ProfiloEmanuela RestaMaria Pia Foschino BarbaroOnofrio RestaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Donato Lacedonia Giulia Scioscia Carla Santomasi Paolo Fuso Giovanna Elisiana Carpagnano Andrea Portacci Franco Mastroianni Giovanni Larizza Eugenio Sabato Emanuela Profilo Emanuela Resta Maria Pia Foschino Barbaro Onofrio Resta Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients
description	Abstract The prognosis of the coronavirus disease 2019 (COVID-19) patients is variable and depends on several factors. Current data about the impact of chronic obstructive pulmonary disease (COPD) and smoking on the clinical course of COVID-19 are still controversial. This study evaluated the prevalence and the prognosis of COPD patients and smokers in a cohort of 521 patients admitted to four intermediate Respiratory Intensive Care Units (Puglia, Italy) with respiratory failure due to COVID-19 pneumonia. The prevalence of COPD and current smokers was 14% and 13%, respectively. COPD patients had a higher 30-day all-cause mortality than non-COPD patients. Former smokers compared to never smokers and current smokers had higher 30-day all-cause mortality. COPD patients and former smokers had more comorbidities. This study described the prevalence and the outcomes of COPD patients and smokers in a homogenous cohort of COVID-19 patients. The study showed that the prevalence of COPD and current smokers was not high, suggesting that they were not at increased risk of getting the infection. However, when SARS-CoV-2 infection occurred, COPD patients and former smokers were those with the highest all-cause mortality, which seemed to be mainly related to the presence of comorbidities and not to COPD and smoking itself.
format	article
author	Donato Lacedonia Giulia Scioscia Carla Santomasi Paolo Fuso Giovanna Elisiana Carpagnano Andrea Portacci Franco Mastroianni Giovanni Larizza Eugenio Sabato Emanuela Profilo Emanuela Resta Maria Pia Foschino Barbaro Onofrio Resta
author_facet	Donato Lacedonia Giulia Scioscia Carla Santomasi Paolo Fuso Giovanna Elisiana Carpagnano Andrea Portacci Franco Mastroianni Giovanni Larizza Eugenio Sabato Emanuela Profilo Emanuela Resta Maria Pia Foschino Barbaro Onofrio Resta
author_sort	Donato Lacedonia
title	Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients
title_short	Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients
title_full	Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients
title_fullStr	Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients
title_full_unstemmed	Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients
title_sort	impact of smoking, copd and comorbidities on the mortality of covid-19 patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/214bc99f4fef4e3e8e845549b9efef60
work_keys_str_mv	AT donatolacedonia impactofsmokingcopdandcomorbiditiesonthemortalityofcovid19patients AT giuliascioscia impactofsmokingcopdandcomorbiditiesonthemortalityofcovid19patients AT carlasantomasi impactofsmokingcopdandcomorbiditiesonthemortalityofcovid19patients AT paolofuso impactofsmokingcopdandcomorbiditiesonthemortalityofcovid19patients AT giovannaelisianacarpagnano impactofsmokingcopdandcomorbiditiesonthemortalityofcovid19patients AT andreaportacci impactofsmokingcopdandcomorbiditiesonthemortalityofcovid19patients AT francomastroianni impactofsmokingcopdandcomorbiditiesonthemortalityofcovid19patients AT giovannilarizza impactofsmokingcopdandcomorbiditiesonthemortalityofcovid19patients AT eugeniosabato impactofsmokingcopdandcomorbiditiesonthemortalityofcovid19patients AT emanuelaprofilo impactofsmokingcopdandcomorbiditiesonthemortalityofcovid19patients AT emanuelaresta impactofsmokingcopdandcomorbiditiesonthemortalityofcovid19patients AT mariapiafoschinobarbaro impactofsmokingcopdandcomorbiditiesonthemortalityofcovid19patients AT onofrioresta impactofsmokingcopdandcomorbiditiesonthemortalityofcovid19patients
_version_	1718381071922364416

Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients

Ejemplares similares